

16 February 2024

ASX Announcement

Largest ever single order

PolyNovo is pleased to announce it has received an order with payment in full for \$US 775k (\$A 1.2m) for product to be delivered into the Ukraine.

The inventory is on hand in the region and ready for despatch. NovoSorb BTM will be used to treat wounded patients numbering in the thousands. The Company anticipates a second order subject to the timely distribution and use of the product.

Chairman, David Williams said: *“Our recent support of countries in conflict zones has attracted interest from charities and foreign governments to financially assist in the provision of life saving devices like NovoSorb BTM. In addition to product, Professor Marcus Wagstaff recently ran a training session for circa 30 Ukrainian surgeons on behalf of the British Orthopaedic Association. This session was taped and translated so the message can be widely shared.”*

CEO, Swami Raote said: *“NovoSorb BTM continues to redefine healing across our world. We are grateful to numerous Surgeons, who have gone close to frontlines to treat the wounded and train Ukrainian surgeons in person/virtually to use NovoSorb successfully in makeshift operation theatre settings. These examples continue to exemplify NovoSorb BTM’s ability to provide superior outcomes across a wide range of dermal defects, in challenging environments.”*

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

About PolyNovo®

PolyNovo is a disruptive medical device company, focused on Advanced Wound Care that designs, develops, and manufactures dermal regeneration solutions (NovoSorb BTM, NovoSorb MTX) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information see polynovo.com

About NovoSorb®

NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb’s unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

Reach

PolyNovo supplies approximately 703 hospitals directly in Australia, Canada, Hong Kong, India, Ireland, the Middle East, New Zealand, Singapore, the United Kingdom, and the United States. Other countries, such as Finland, France, Germany, Spain, and Turkey are serviced by a distributor.